

PPSV23

Vaccine	Dosage & Administration	Primary Schedule	Recommended Age	Indication for Use
Pneumovax®23 (Merck)	0.5 mL IM	Single dose with revaccination of some individuals*	2 years and older	Vaccination against invasive pneumococcal disease types included in the vaccine.



Pneumococcal Polysaccharide Vaccine (PPSV23) Recommendations

General Recommendations:

- All adults 65 years of age and older.
- Anyone 2 through 64 years of age who has a long-term health problem such as:
 - ✓ heart disease
 - ✓ sickle cell disease
 - ✓ alcoholism
 - ✓ cerebrospinal fluid leaks or cochlear implant
 - ✓ lung disease
 - ✓ diabetes
 - ✓ cirrhosis
- Anyone 2 through 64 years of age who has a disease, condition or is taking a drug or treatment that lowers the body's resistance to infection, such as:
 - ✓ Hodgkin's disease
 - ✓ kidney failure
 - ✓ nephrotic syndrome
 - ✓ organ transplant
 - ✓ long-term steroids
 - ✓ radiation therapy
 - ✓ lymphoma or leukemia
 - ✓ multiple myeloma
 - ✓ HIV infection or AIDS
 - ✓ damage spleen, or no spleen
 - ✓ certain cancer drugs
- Any adult 19 through 64 years of age who:
 - ✓ is a smoker (should also receive smoking cessation counseling)
 - ✓ has asthma

*Recommendations for a Second Dose of PPSV23:

- A second dose is recommended for people 65 years and older who got their first dose when they were younger than 65 years and it has been 5 or more years since the first dose. If first dose is received at age \geq 65 years, no further doses are indicated.
- A second dose is recommended 5 years after the first dose for people 2 through 64 years of age who:
 - ✓ have sickle-cell disease
 - ✓ have HIV infection or AIDS
 - ✓ have had an organ or bone marrow transplant
 - ✓ have cancer, leukemia, lymphoma, multiple myeloma
 - ✓ are taking medication that lowers immunity (such as chemotherapy or long-term steroids)
 - ✓ have a damaged spleen or no spleen
 - ✓ have nephrotic syndrome

Contraindications

- A serious allergic reaction to a vaccine component or following a prior dose
- Pregnancy

Precautions

- A moderate or severe acute illness until condition improves/resolves

Adverse Reactions

- **Local:** redness or pain at administration site
- **Systemic:** fever, muscle aches, or more severe local reactions

Storage & Handling

- Store vaccine between 35° and 46°F (aim for 40°F)
- DO NOT freeze vaccine



PPSV23 Recommendations for High-Risk Children 2-18 Years Previously Immunized with PCV7 or PCV 13 (Pneumococcal Conjugate Vaccine):

- Children who have previously received pneumococcal conjugate vaccine (PCV) and who are among risk groups for which PPSV23 is recommended should receive one dose of PPSV23 at age 2 years (at least 2 months after the last dose of PCV), as they will benefit from additional pneumococcal serotypes included in PPSV23. (See Table 1)
 - ✓ In addition, immunocompromised children or children with sickle cell disease or functional or anatomic asplenia should receive a second dose of PPSV23 five years after the first dose of PPSV23.
- Routine use of PPSV23 after PCV is not recommended for Alaska Native or American Indian children aged 24 through 59 months. However, in special situations, public health authorities may recommend the use of PPSV23 after PCV FOR Alaska Native or American Indian children aged 24 through 59 months who are living in areas in which risk of invasive pneumococcal disease is increased.
- When elective splenectomy, immunocompromising therapy, or cochlear implant placement is being planned, PCV13 and or PPSV23 vaccination should be completed at least 2 weeks prior to surgery or initiation of therapy.

Table 1.

Age	Number of Doses PCV7 Doses	Number of PCV 13 Doses	Number of PPSV Doses
24 – 71 months with an underlying medical condition	Less than 3 doses before 24 months of age	2 doses, one dose 8 weeks after the most recent dose and another dose 8 weeks later	1 dose at least 8 weeks after the last dose of PCV 13
24 – 71 months with an underlying medical condition	Any incomplete schedule of 3 doses before 24 months of age	1 dose 8 weeks after the most recent dose	1 dose of PPSV at least 8 weeks later